StonvexLoading…
StonvexStonvexStonvexCore line items from ACLS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $198.96M | $839.05M | $600.72M | $387.11M |
Operating Income | $7.95M | $119.31M | $83.14M | $58.12M |
Net Income | $9.21M | $120.24M | $85.94M | $31.38M |
EPS (Diluted) | $0.30 | $3.80 | $2.70 | $1.87 |
Total Assets | $1.37B | $1.36B | $1.35B | $1.32B |
Total Liabilities | $329.90M | $326.67M | $331.80M | $301.10M |
Cash & Equivalents | $150.83M | $145.45M | $187.50M | $173.65M |
Free Cash Flow OCF − CapEx | $16.30M | $107.01M | $115.91M | $72.58M |
Shares Outstanding | 30.73M | 30.72M | 31.00M | 31.42M |